Paul Romness
Publishes 3 feeds
All News
All News
10 posts · contributor
Drug Development News
Drug Development News
10 posts · contributor
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances
10 posts · contributor
Lately
Roche pours $750M into Oregon manufacturing plant as obesity push expands
Roche pours $750M into Oregon manufacturing plant as obesity push expands
All News ·
Scribe’s early-stage IPO standout defies biotech’s derisking trend
Scribe’s early-stage IPO standout defies biotech’s derisking trend
All News ·
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
All News ·
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
FDA News: Approvals, Adcomms, Complete Response Letters and Guidances ·
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
Ultragenyx bags first gene therapy approval as previously rejected Sanfilippo asset awaits decision
All News ·
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
All News ·
Everything on this page was read from markup Paul Romness published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON